Trends in the development of oral anticoagulants. - Wikidata - awgldk - TriplyDB

Trends in the development of oral anticoagulants.

Trends in the development of oral anticoagulants.

http://www.wikidata.org/entity/Q33424198

about

Trends in the development of oral anticoagulants.

http://www.wikidata.org/entity/Q33424198

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Trends in the development of oral anticoagulants.

@ast

Trends in the development of oral anticoagulants.

@en

type

label

Trends in the development of oral anticoagulants.

@ast

Trends in the development of oral anticoagulants.

@en

prefLabel

Trends in the development of oral anticoagulants.

@ast

Trends in the development of oral anticoagulants.

@en

P1433

Q33424198-5B65D835-06B9-4E51-97A0-A407EE9A243C

P1476

Q33424198-653A2868-E339-4E37-9AB5-600E86C2AD20

P2093

Q33424198-2601D776-382C-4146-926C-09700B590F6F

P2860

Q33424198-0492EFDD-FC6E-4F72-AD42-0CADF909BE1F

Q33424198-06ED9C3C-5941-49C9-B372-61581BD2B5EE

Q33424198-0A873159-B1E3-4756-8915-284A8547C8C7

Q33424198-0ACE1772-6901-4589-9BE8-85464FC20BB3

Q33424198-0D53E8C3-1ED5-4CDB-B782-44522F62C724

Q33424198-138D1BC1-0363-4E8A-AB37-2B90154041C5

Q33424198-145BE7E2-1D01-459C-8DE1-356CE2D44B00

Q33424198-1C2B31B3-401E-4682-AB21-31FA5698BDBC

Q33424198-1E048080-820E-4AD3-9EA5-27DF51246362

Q33424198-2733AEF9-8ADB-4CA9-A4FB-0E3BD9F9072C

P304

Q33424198-F7B85773-1171-4D06-AB2E-43467568E40B

P31

Q33424198-44EC36C9-7CD3-4F4E-8BF3-AF6DB96BC931

P356

Q33424198-AF486BAC-2A76-4A00-8522-DE73B3D03CC6

P433

Q33424198-7E7945A3-5141-4286-93DC-4217A68A7782

P478

Q33424198-1CC5033D-E3C6-4555-8E27-92408C062FB4

P50

Q33424198-3624E1CD-3ADE-492D-B11E-DBFEBE34F64B

Q33424198-41603E02-8A3C-4326-BE9D-F49161E00FAE

Q33424198-B69CF5F1-CC0F-40D1-B0F0-F0D1052D2817

P577

Q33424198-687E704A-DADF-4995-BDFA-45126DA2AD09

P698

Q33424198-A09DD99D-7A2A-4AAB-9F91-0930259603D9

P921

Q33424198-74D96652-5F0E-4D23-BD9F-0C92EBECA817

P356

P1433

Therapeutic delivery

P1476

Trends in the development of oral anticoagulants.

@en

P2093

Bettina Ralay-Ranaivo

http://www.w3.org/2001/XMLSchema#string

P2860

The anticoagulant activation of antithrombin by heparin

Structure-based design of novel potent nonpeptide thrombin inhibitors

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

Dabigatran versus warfarin in patients with atrial fibrillation

New anticoagulants for treatment of venous thromboembolism

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo.

Update on heparin: what do we need to know?

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

P304

685-703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/TDE.15.22

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Couvreur

Delphine Borgel

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26149785

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation